Title:
A cure for rheumatoid arthritis
Document Type and Number:
Japanese Patent JP6239517
Kind Code:
B2
Abstract:
Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to Tyr-Leu-Asp-Phe-Gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (GM-CSFRα). Use of GM-CSFRα inhibitors such as mavrilimumab to enhance clinical benefit in RA patients receiving stable dose of DMARDs, particularly methotrexate.
Inventors:
Godwood, Alex
Fabrin, Maglini
Fabrin, Maglini
Application Number:
JP2014533950A
Publication Date:
November 29, 2017
Filing Date:
October 10, 2012
Export Citation:
Assignee:
Medimun Limited
International Classes:
A61K39/395; A61K31/519; A61K31/573; A61K45/00; A61P19/02; A61P29/00; A61P43/00; C07K16/28
Domestic Patent References:
| JP2009533020A | ||||
| JP2011522795A | ||||
| JP2009545546A | ||||
| JP2008500334A |
Foreign References:
| WO2011097301A2 |
Other References:
Ann. Rheum. Dis.,2011年 5月25日,Vol.70, No.9,p.1542-1549
Attorney, Agent or Firm:
Yusuke Hiraki
Satoshi Fujita
Eiichi Arai
Natsuo Tanaka
Naoko Kikuta
Nozomi Murabayashi
Satoshi Fujita
Eiichi Arai
Natsuo Tanaka
Naoko Kikuta
Nozomi Murabayashi